Chimeric antigen receptor T cell (CAR T) therapies are ‘living drugs’ in which T cells are genetically engineered to recognize and kill cancer cells. A major barrier to progress for CAR T targeting li...

March 7, 2025. Washington DC and nationwide. Because science is for everyone.

Main Finding: A phase I trial supported the safety and feasibility of repeated intracranial infusions of B7-H3 CAR T cells for DIPG.Concept: B7-H3 is an immunoregulatory protein expressed on the surfa...

The 2025 SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiting challenges that impede bringing the...

ACLY-deficient CAR T cells targeting the tumor-associated antigen disialoganglioside GD2 (GD2 CAR T cells) also resisted acquiring TEX-like properties, exhibiting reduced CD39 expression when co-cultu...

Preliminary findings in seven patients with mismatch repair-proficient metastatic colorectal cancer who were treated in the context of a phase 2 trial show that adoptive transfer of autologous periphe...

Modulation of exhausted CD8+ T cell differentiation by targeting TET2 improves therapeutic potential of CAR T cells in cancer.

Chimeric antigen receptor (CAR) T cells are highly effective in hematologic malignancies. However, l

Instantly find and follow the same users from your Twitter follows on Bluesky.